AU2011242990B2 - Compositions and methods for prediction of drug sensitivity, resistance, and disease progression - Google Patents

Compositions and methods for prediction of drug sensitivity, resistance, and disease progression Download PDF

Info

Publication number
AU2011242990B2
AU2011242990B2 AU2011242990A AU2011242990A AU2011242990B2 AU 2011242990 B2 AU2011242990 B2 AU 2011242990B2 AU 2011242990 A AU2011242990 A AU 2011242990A AU 2011242990 A AU2011242990 A AU 2011242990A AU 2011242990 B2 AU2011242990 B2 AU 2011242990B2
Authority
AU
Australia
Prior art keywords
disease
sample
cells
modulator
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011242990A
Other languages
English (en)
Other versions
AU2011242990A1 (en
Inventor
Cirilo Cabradilla
Douglas P. Clark
Adam Schayowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarker Strategies LLC
Original Assignee
Biomarker Strategies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarker Strategies LLC filed Critical Biomarker Strategies LLC
Publication of AU2011242990A1 publication Critical patent/AU2011242990A1/en
Application granted granted Critical
Publication of AU2011242990B2 publication Critical patent/AU2011242990B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011242990A 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression Ceased AU2011242990B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15
PCT/US2011/032935 WO2011133477A2 (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Publications (2)

Publication Number Publication Date
AU2011242990A1 AU2011242990A1 (en) 2012-11-01
AU2011242990B2 true AU2011242990B2 (en) 2015-02-12

Family

ID=44834747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011242990A Ceased AU2011242990B2 (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Country Status (12)

Country Link
US (1) US9766249B2 (OSRAM)
EP (1) EP2561368B1 (OSRAM)
JP (2) JP6158078B2 (OSRAM)
KR (1) KR101977875B1 (OSRAM)
CN (2) CN108535465A (OSRAM)
AU (1) AU2011242990B2 (OSRAM)
CA (1) CA2795362C (OSRAM)
ES (1) ES2650674T3 (OSRAM)
HK (1) HK1258688A1 (OSRAM)
PL (1) PL2561368T3 (OSRAM)
SG (1) SG184507A1 (OSRAM)
WO (1) WO2011133477A2 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
EP3052129A2 (en) * 2013-09-30 2016-08-10 Daiichi Sankyo Company, Limited Protein biomarker and uses thereof
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
JP6910339B2 (ja) * 2015-07-07 2021-07-28 ジェネンテック， インコーポレイテッド 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
US20200325543A1 (en) * 2017-11-20 2020-10-15 Tolremo Therapeutics Ag Diagnostic method
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Llc Novel gene classifiers and uses thereof in skin cancers
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
GB201914517D0 (en) * 2019-10-08 2019-11-20 Randox Laboratories Ltd Xbp1 isoform multiplex assay
JP2023537260A (ja) * 2020-07-24 2023-08-31 ジェネンテック， インコーポレイテッド バイオマーカーを使用する骨髄穿刺液の血液希釈の決定
US20240167102A1 (en) * 2021-03-02 2024-05-23 Dermtech, Inc. Predicting therapeutic response
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR20240037082A (ko) * 2022-09-14 2024-03-21 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143183A2 (en) * 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
US20080293069A1 (en) * 2004-08-31 2008-11-27 Piotr Kulesza Rapid prognostic assay for malignancies treated with epidermal growth factor receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
KR101381331B1 (ko) 2005-05-09 2014-04-04 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
JP5208730B2 (ja) * 2005-05-18 2013-06-12 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
CN101194027B (zh) 2005-06-08 2012-10-24 日立化成研究中心公司 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法
WO2007028005A2 (en) 2005-09-01 2007-03-08 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
EP2899541A1 (en) * 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US20090098594A1 (en) * 2007-08-21 2009-04-16 Nodality, Inc. Methods for diagnosis prognosis and methods of treatment
EP2210080B1 (en) 2007-10-24 2015-01-28 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293069A1 (en) * 2004-08-31 2008-11-27 Piotr Kulesza Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
WO2007143183A2 (en) * 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARK, D. P., Expert Rev. Mol. Diagn., 2009, vol. 9, no. 8, pages 787-794 *
CLARK, D., Abstract SP165, European Journal of Cancer, 2009, vol. 7, no. 4, page 2 *
JIMENO, A. et al., Oncogene, 2009, vol. 28, pages 610-618 *
LAVALLIE, E. R. et al., Current Opinion in Pharmacology, 2008, vol. 8, pages 647-653 *

Also Published As

Publication number Publication date
JP6158078B2 (ja) 2017-07-05
JP6580546B2 (ja) 2019-09-25
WO2011133477A2 (en) 2011-10-27
PL2561368T4 (pl) 2018-03-30
CA2795362C (en) 2018-03-20
EP2561368B1 (en) 2017-08-02
WO2011133477A3 (en) 2012-05-10
CA2795362A1 (en) 2012-10-02
HK1258688A1 (zh) 2019-11-15
US9766249B2 (en) 2017-09-19
CN102947706B (zh) 2018-04-13
EP2561368A4 (en) 2013-10-09
KR101977875B1 (ko) 2019-05-13
CN108535465A (zh) 2018-09-14
US20120094853A1 (en) 2012-04-19
ES2650674T3 (es) 2018-01-19
JP2013525786A (ja) 2013-06-20
AU2011242990A1 (en) 2012-11-01
SG184507A1 (en) 2012-11-29
KR20130095183A (ko) 2013-08-27
CN102947706A (zh) 2013-02-27
JP2017106923A (ja) 2017-06-15
EP2561368A2 (en) 2013-02-27
PL2561368T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
US9766249B2 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
JP7108323B2 (ja) 細胞全体でのアッセイおよび方法
JP6782698B2 (ja) がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
Freeman-Cook et al. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Shiau et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment
JP7485391B2 (ja) 治療剤選択のためのシグナル伝達経路活性の測定方法
WO2015089380A2 (en) Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
Dinney et al. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum
Lee et al. High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them
Kavak et al. Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets
Bellot et al. Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients
Hammond et al. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003
Ma et al. Identification of gene expression profiles associated with doxorubicin resistance in paired doxorubicin-resistant and doxorubicin-sensitive osteosarcoma cell lines
Salarian et al. Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer
Zhang et al. Electrochemical sensor medical diagnosis assisted simulation LINC00115 exerts oncogenic function in triple negative breast cancer via regulation of TM9SF
Jacobo Transcriptional Programming as a Determinant of Differential Drug Sensitivity in Breast Cancer
Young A translational study in pancreatic neuroendocrine neoplasms
WO2025045997A1 (en) Drug screening using a responsome profile generated on subject-derived samples
KR20240051492A (ko) 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법
CN121905356A (zh) 基于krtdap计算机辅助诊断或筛选药物的方法、系统、设备、介质或程序产品
Ly et al. epithelial cells [version 1; referees: awaiting peer review]

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired